Atif Rahim - Head of Investor Relations Joseph Flanagan - President and CEO Christopher Ricaurte - CFO and Treasurer.

Charles Rhyee - Cowen & Company Steven Halper - Cantor Fitzgerald.

Good morning. My name is Lisa, and I’ll be your conference operator today. At this time, I would welcome to the R1 RCM First Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent background noise. [Operator Instructions]. Thank you. Atif Rahim, Head of Investor Relations, you may begin your conference..

Thank you, operator. Good morning, everyone, and welcome to the call. We’ll start with prepared remarks by Joe Flanagan, R1’s President and CEO; and Chris Ricaurte, CFO and Treasurer. We’ll then turn it over to Q&A. Today’s conference call is being recorded.

And as a reminder, certain statements made during the call may be considered forward-looking statements pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995.

In particular, any statements about our future growth, plans and performance, including statements about our forecast for 2018, expected benefits from the Intermedix acquisition and expected new business are forward-looking statements.

These statements are often identified by the use of words such as anticipate, believe, estimate, expect, intend, design, may, plan, project, would and similar expressions or variations.

The forward-looking statements made on today’s call are based on R1’s current expectations and projections all future events as of today only and should not be relied upon as representing the company’s views as of any subsequent date.

Subsequent events and developments, including actual results or changes in our assumptions, may cause our views to change. While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so, except to the extent required by applicable law.

Investors are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements made on today’s call involve risks and uncertainties.

Our actual results and outcomes could differ materially from those included in these forward-looking statements as a result of various factors, including but not limited to the factors discussed under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2017. Now, I’d like to turn the call over to Joe..

registration, coding, acuity capture, billing and follow-up and collections. In addition, Intermedix brings a managed services offering for practice management.

This is important for our customers since we now support administrative functions like physician credentialing, payer benchmarking and payer negotiations, as well as provide the required physician analytics to maximize a practices financial performance.

For quite some time, we have talked about the value and need for an integrated physician acute revenue cycle offering in the market. There are many vendors serving the acute space or the physician space separately, but less than a handful with an integrated offering across both settings.

Our view, supported by market checks, is that providers are increasingly fatigue with multiple vendors. What large health systems are looking for is a revenue cycle partner who is aligned with their operational goals and mission.

Results from a market research study we conducted confirms our view that the R1-Intermedix combination enhances our positioning at the strategic commercial infrastructure partner of choice for large IDMs. This market positioning is centered around five provider needs.

First, they are seeking a unified solution across physician offices and hospital settings to reduce their administrative burden and improve financial performance.

Second, the comprehensive nature of our solution, which include services infrastructure and technology, applied across all care settings and payment models is valuable to integrated delivering networks. Third, they appreciate flexibility and different options when it comes to contract structure.

Fourth, they want to see continued innovation, like what we have done with the patient experience platform and Intermedix has done with Analytics. And fifth, a track record of strong performance and a willingness to allow performance incentives in the contract structure.

Now that the acquisition is closed, we started to implement our integration plans. From an external standpoint, we’ll start by connecting the two brands to highlight our positioning along the lines I just discussed. Over time, we plan to transfer the Intermedix brand equity over to R1.

From an internal standpoint, our efforts are focused on the following four areas. First, we intent to make additional investments to drive organic growth in the core business lines at Intermedix.

We also intent to prioritize investments to commercialize the integrated revenue cycle platform through R1’s existing commercial channel and target customer base. Second, we are coordinating resources across both companies to deploy the Ascension Medical Group contract.

We expect the contract to be signed by the end of the second quarter, work is well underway and the first phase of Ascension Medical Group, namely the Wisconsin market, which we announced last May and deployed in Q1 of this year. Third, realized synergies from the transaction.

We expect $15 million in annualized cost savings, higher than the $10 million when we announced the acquisition because of additional opportunities identified in in operations and SG&A. Fourth, we’ll integrate two strong technology portfolios that view as highly complementary and mutually reinforcing.

We see significant announces to our existing automation, analytics and data visualization capabilities. On our last call, we discussed our ongoing efforts with robotic process automation, or RPA technology.

Intermedix has utilized advanced technology to automate processes, which we will leverage to give our operators the ability to automate processes without having to write actual code. Intermedix’s performance monitoring and optimization for RPA has also advanced and expands our collective capabilities.

Our portfolio of automated processes more than doubles, and we can cross-supply our automation between the businesses to gain efficiencies. For example, both acute and physician revenue cycle teams often need to retreat and send medical records to insurance companies after filing initial claim.

Even with electronic records, this can be manual process, especially for centralized business offices covering distributed facilities.

But this is a process that Intermedix, with its very high distribution of client facilities, has have to automate with robotics and we now see a potential opportunity to leverage that across for acute locations as well. This is just one potential example of where we can mutually benefit from each other’s technologies.

On the analytics front, while we utilize sophisticated analytics to drive yield at the lowest possible cost in the inpatient environment, Intermedix has applied data science and predictive analytics to the ambulatory environment, where their solutions strive results inside physician practices.

For example, they drive physician revenue capture, optimize the schedule with no-show prediction and improve the overall operations of running a physician practice. Turning to our technology initiatives more broadly. We continue to invest aggressively to further strengthen and expand our competitive position.

In the first quarter, we continue to make progress relative to our technology roadmap for the year. For our patient and physician experience platform, which we officially launched at HIMSS earlier this year, we expanded our scheduling platform to 6 hospitals and 24 physician practices.

We continue to see users opt on for online or mobile self-service generally over 45% of the time. If you recall from our comments on the last earnings call, this is well above the 20% expectation we had, and it's encouraging to see the higher numbers sustained as we roll out more broadly because of results in savings directly to our bottom line.

We also continue to round out our technology across settings of care. In addition to what Intermedix brings to the table, we’ve completed development of our R1 Access, R1 Link, R1 Decision and R1 Contract applications to make them fully suited to both the acute and physician revenue cycle environments.

Lastly, from a scalability perspective, we've developed an accelerated deployment solution designed to cut our customers' IT implementation hours by more than 50% and significantly accelerate time-to-value creation at each new deployment, one of the reasons for significant upfront deployment costs at a new customers that technology has historically taken a long time to implement and has required significant IT resources to interoperate with the existing host systems.

We're in the process of transitioning our deployment approach to this new accelerated model for our coming deployments. In addition to cutting implementation hours, we are also focused on accelerating time-to-value and other deployment functions.

In 2017, we deployed more than $8.5 billion in new NPR across 71 facilities, added 4,700 employees and completed more than 400 installs of our core R1 Hub solution. We’ve taken a learnings from these deployments and translated this into accelerating our deployment timeline.

Intermountain is a good example of how we’ve compressed our cycle time from contract signing to deployment. Since signing the operating [partner] agreement in late January and commencement of the new contract in early April, we transitioned 2,300 employees from Intermountain to R1.

This was accomplished within 10 weeks, approximately 35% faster than our historical rate. In connection with these transitions, we held 70 What to Expect meetings in one week across Intermountain facilities, vendor rationalization also began shortly after contract deployment versus 90 to 120 days later in the past.

Finally, in terms of optimizing the location where work is performed, we expect to be at target in approximately seven months or 20% faster than our prior target. Our next deployment is Presence Health. We expect a contract to be signed in Q2, and similar to Intermountain, we are investing early in our deployment efforts.

We have mobilized our deployment teams to begin planning for employee transitions, technology implementation and standardization of work. We expect this early investment to pay dividends later when we begin the full-scale deployment activities.

For the rest of our business, Ascension Phase I and Phase II ministries are tracking ahead of our operating partner model target profitability. We are keenly focused on generating incentive fees by meeting or exceeding the target key performance metrics.

Across Phase 1 and Phase 2 ABMs, we have seen meaningful improvement in a number of metrics, with double-digit improvement in [HAR], bad debt and denials. Lastly, let me touch on our commercial efforts.

Our commercial efforts are on full gear, as the market reengagement strategy initiated by Gary Long and his team in Q4 of last year is translating to overall qualified pipeline growing by more than 300% since that time. The pipeline is comprised of health systems interested in both end-to-end enterprise-wide services or modular services.

The expansion of Beacon Health for Revenue Capture services is an example of interest in and compelling value preposition of our modular services. In addition to new contracts we have previously announced, we added three customers to our past client base in the first quarter.

We anticipate continued growth and conversion of our pipeline as the year progress. In closing, I’d like to emphasize that ensuring we stay on track with our onboarding goals and successfully integrating Intermedix are critical priorities for us.

We also remain committed to investing in our technology to drive automation and enhance our overall capabilities, while maintaining a continued focus on execution across our customer base.

We continue to be very optimistic about the prospects of the business, given our differentiated value preposition, favorable end-market dynamics and the associated traction we are seeing with our commercial efforts. Now I’d like to turn the call over to Chris. .

Thank you, Joe, and thank you all for joining us. I’d like to remind everyone that following the early adoption of ASC 606 at the start of 2017, our GAAP revenue is now comparable to year-ago numbers, and we won’t be using some of the non-GAAP metrics we have used over the past few years.

We will continue to present adjusted EBITDA as a non-GAAP metric. The adjustments to EBITDA to arrive adjusted EBITDA, are the addition of stock-based compensation expense, transaction-related costs and certain other costs. Additionally, the cost of services and SG&A numbers are referenced on today’s call on a non-GAAP basis.

A reconciliations of GAAP to non-GAAP financials is available in today's earnings press release. Now turning to Q1 results. Revenue for the quarter was $147.3 million, up $7 million sequentially and up $60.4 million year-over-year.

The onboarding of Ascension physician business in Wisconsin in a fourth quarter contributions from the rest of the Wisconsin market drove sequential revenue growth in net operating fees. PAS revenue, which is now consolidated into the other lines, grew $400,000 sequentially.

Looking now to the rest of the year, we expect a meaningful step-up in the second quarter driven by the contribution from the Intermountain and Intermedix. We expect a further step-up in the third quarter driven by a full quarter of Intermedix contribution, onboarding of Presence Health.

We also expect to onboard the Ascension Medical Group in the late Q3/early Q4 timeframe, which should also result in sequential increase in the fourth quarter. From a cost standpoint, cost of services in Q1 were $132.8 million compared to $121.9 million in Q4 of last year.

This increase was largely driven by the new business in Wisconsin as well as upfront cost to support onboarding of the Intermountain business and the anticipate Presence Health and Ascension Medical Group business.

SG&A expenses in Q1 were $14.1 million, up $1.4 million sequentially, driven by legal costs related to prior litigation and continued investment in sales and marketing as well as our corporate IT infrastructure.

We'll continue to remain disciplined in our SG&A structure, with most of the incremental budget for 2018 versus 2017 allocated to sales and marketing efforts. Adjusted EBITDA for the quarter was $0.3 million compared to $5.7 million in the fourth quarter and up from negative $1.4 million a year ago.

The sequential decline is a result of expected seasonality coupled with the upfront contract onboarding costs we've discussed.

When you look the contribution from the CBMs in Phase 1 ABMs, in other words, contracts that were deployed a year or more ago, the EBITDA contribution from these customers on a same-store basis was up $6 million year-over-year and ahead of pace in terms of targeted profitability margin rates.

Lastly, we incurred $2.4 million in other costs in Q1, primarily related to the Intermedix acquisition. These costs are not reflected in adjusted EBITDA, but are included in the other expenses line on our GAAP income statement. Turning to the balance sheet.

Cash at the end of March inclusive of restricted cash was $171 million, up from $166 million at the end of December. This increase was driven by the equity investment by Intermountain in Q1, offset by cash used for CapEx and working capital needs.

In connection with the Intermedix acquisition, we utilized approximately $105 million in cash from our balance sheet to fund the acquisition and paid for transaction-related cost. Turning to our outlook for 2018. We are reaffirming the preliminary 2018 guidance we provided in conjunction with the announcement of the Intermedix acquisition in February.

We continue to expect to generate revenue of $850 million to $900 million and adjusted EBITDA of $50 million to $55 million. This guidance is preliminary as it does not contemplate any major changes from adoption of ASC 606 for Intermedix.

We plan to announce the effects of ASC 606 accounting on Intermedix revenue stream on our second quarter earnings call. We continue to expect the majority of EBITDA for the year to come through in the second half, given continued upfront investments in the second quarter to onboard our new business.

In closing, I am pleased to say we are tracking well relative to our expectations. We are making the required investments to successfully onboard close to $9 billion in new patient revenue this year and look forward to executing on our commitments in 2018. Now, I’ll turn the call over to the operator for Q&A.

Operator?.

Thank you. [Operator Instructions] Our first question comes from the line of Charles Rhyee from Cowen & Company. Your line is open..

Hey, guys. Thanks for taking the question. Maybe, Joe, talk about sort of - you talked about the funnel and the qualified leads and it sounds great that things are growing again.

Can you talk about sort of what the conversations are like? As you know, if we recall few years back, you were in discussions with a numerous field -- things have stalled obviously. Obviously, this year things have started to pick up again.

Can you talk about how those conversations are going and what’s changed about it? And maybe talk about to the extent how Ascension has been involved in any of these discussions. That be helpful..

What does the journey look like? What step one, step two, step three, what are the requirements the customer needs to be prepared to provide or support? And how would this process occur as it relates to the operating model partnership? And I view that generally as positive, because I think it indicates a bias for action from the customer’s standpoint.

And I would say that’s a general theme that we’re seeing.

The second thing I would say is, there definitely appears to be -- and I think this plays to the strength of our model, and understanding that preparing the revenue cycle infrastructure for the complexity that is coming or is there today is a high priority, but the funding envelops to do that are really constrained.

And so our model where we’re able to really be aligned and drive results and have a progression of our earnings as we drive those results, I think plays well vis-à-vis other models that are in place. And I think the increasing pressures that our customers are having to navigate financially lend them to be very, very open to those discussions.

So that's how I would characterize the pipeline discussions, Charles. .

Thanks for that.

And if you talk about the Ascension, Ascension is evolving in helping - in any kind of the discussions you had with clients, they are along with you at times to talk about sort of the their experience with you guys?.

They are. But again, maybe in a comparing contract, if I do that over the trailing 8 quarters, I would say second half of '16 and the bulk of '17 Ascension was heavily involved with us as we were relaunching the company and reestablishing credibility with our market. And they were unbelievably helpful in that period.

They continue to be helpful when we need their support or when we want to have a reference, discussion, et cetera.

But equally, I would say, and I would characterize this also as very encouraging from my vantage point, as Gary has built out his commercial organization and built out the processes and the human capital to drive the growth in the pipeline, I'm encouraged that more and more of our discussions are driven off of those efforts.

And we always have the support and willingness of Ascension to engage and just share their learnings that have occurred with us, both positive and where those areas of improvement, which I think is a very credible perspective to our target customers.

But Gary has done a very nice job, again, to build out the commercial engine in the channel, and he's more and more carrying those discussions with the support of the company and the capabilities and the value prop we have to bring to the market. .

Great. Thanks. And maybe one last question then this. When we look at the balance sheet and the cap structure right now, we saw this preferred stock out there with the paid and kind on the coupon.

Can you remind us of how many is left on the pick, the paid stock, and anything there you guys do maybe to kind of restructure this? Because I feel sometimes away that the complexity of the cap structure makes it difficult for some of the market to kind of get the arms around a little bit. Anything that you share with us would be great. .

Yes, Charles. This is Chris. I'll talk to the timing, and it goes out to 2023. So 5 years left. And Joe can talk a little bit about the second half of your question. .

Yeah. Charles, from a cap structure evolution -- and we fully understand the questions and the thoughts around this from a broader investor base.

What I would say, we're focused right now, and we see just a great end market and we feel really good about our value prop, so we're focused right now on driving growth and that growth we think is the lever that we're in full control of as a management team to drive earnings and offset the evolution of that cap structure, if you will.

But as we progress through the balance of this year and head into the term from ’18 to ‘19, we’ll continue to engage in those discussions at our board and look at some the opportunities and the thoughts on evolution of the cap structure.

But right now our primary focus, and we’re very encouraged by our competitive positioning, by the end market and by the capability the company has is really just to drive the growth of the business on the top line and the bottom line from that perspective. .

Okay, great. Thanks a lot, guys. Appreciated. .

[Operator instructions] Our next question comes from the line of Steven Halper from Cantor Fitzgerald. Your line is open. .

Hi, good morning.

Could you just talk about the terms on the debt deals that you completed for Intermedix?.

Sure. So there was a first lien debt, the seven-year term with that LIBOR plus 525 basis points, and so that was the $270 million. And there was a subordinated debt, which was a combination of the Ascension, TowerBrook and Intermountain, and that was that 14%, and again a similar term.

So those are the two pieces that add up to the $380 million of debt. .

And the private debt with Ascension and Intermountain, that’s a pick as well, right?.

It’s a pick. It’s a pick [Indiscernible], but that’s the option of the company to pay that in lieu of paying cash. So our expectations we’ll pay cash. But in this case, it’s that optionality. .

Okay, good. That’s helpful. Thank you. .

Thanks, Steve. .

There are no further questions at this time. Mr. Flanagan, will turn the call back over to you. .

Thank you, operator, and thank you, everybody, for joining us. To close out the call, I’d like to say that given the upfront investments we have made, we are in a very good position to onboard the new business that’s been contracted and committed to us.

We expect dividends from these investments to start flowing through over the coming quarters, in line with my comments and Chris’s comments, and we’re looking forward to integrating and broadening our offering and solution set. We look forward to keeping you updated on the ongoing basis - on an ongoing basis as we progress through the year.

I just want to say thank you very much. And operator, we can close the call. .

Thank you. This concludes today’s conference call. You may now disconnect..